Australia's largest stock trading and investment forum Australia's #1 stock forum

NEU

0.15%

$13.13 neuren pharmaceuticals limited

Neuren Media and Analyst Coverage, page-1312

First 1312 Last

Share
Profile

Follow
Tony barber

6,531 Posts.

720

17/08/24

17:32

Post #: 75252570
Share

Originally posted by Taurean7 ↑

Neuren has indicated its ethical priority to have its products available for disease sufferers as early as possible. This would be a major factor in any decision to accept an early takeover offer from a suitor able to do that.

With an apparent suite of neurological indications able to be addressed by the NNZ-2591 platform, any attempt by Neuren alone to develop them will be heavily constrained by costs, and timelines to patients would suffer considerably as a result.

One way of relieving ethical pressure to accept a premature offer would be the partnering or full sale of lower priority assets, while maximising value to NEU shareholders through full development of other selected indications. Funds received from the former would support the latter.

Phelan-McDermid and Pitt-Hopkins appear to be the indications prioritised for full development at this stage.

With Phase1 already achieved for NNZ-2591, any new indications post pre-clinical can enter the clinic at the higher value Phase2 level, and the same selective strategy can be applied to their development.

Such a strategy would indicate to a potential suitor that Neuren is capable of sustaining the long-term development of its assets, and therefore would be well placed in any TO negotiations as a result.

Expand

Jon said just 2 weeks ago that he doesn't necessarily believe that anyone else can develop NZZ2591 faster than NEU can.

NEU Price at posting: $15.57 Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

What's causing the cost-of-living crisis, and how to navigate it

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk